PGY-2 Oncology Resident Munson Healthcare Traverse City, Michigan, United States
Poster Abstract:
Background: Bispecific T-cell engager therapy is a novel cancer treatment, having exemplified its efficacy within the realms of acute lymphocytic leukemia, B-cell lymphomas, and multiple myeloma. In terms of objective response to treatment, bispecific therapy across the board achieves therapeutic responses far above that of traditional therapy in the relapsed or refractory setting and is approaching response rates close to that achieved by CAR-T therapy. This novel treatment avoids the delayed time to treatment seen with CAR-T when waiting to receive individualized T-cells back from the manufacturer. Bispecific therapy also presents as a more accessible subsequent line option for multiple myeloma or lymphoma patients who are not geographically near an academic medical center that performs CAR-T therapy. We are purposing how smaller, community-centered hospitals can safely initiate inpatient ramp up of bispecific therapies, carefully manage and monitor patients with any neurotoxicity or cytokine release syndrome, and efficiently transition these patients to outpatient treatment with subsequent cycles. Implementing a bispecific therapy program at smaller, community cancer centers will allow patients to remain closer to home, to their support systems, as well as cut down on patients’ travel expenses.
Objectives: - Educate eligible patients and caregivers on the selected bispecific regimen, emphasizing the pharmacist’s role in follow-up and monitoring of the patient - Create a post-hospitalization survey for patients to complete assessing their experience - Create a pre- and post-survey for oncology nursing staff and providers to complete assessing their experience and knowledge of the newly implemented bispecific therapy program - Implement and educate patients on Equicare®, an application where patients will record daily clinical vital signs and complete a daily toxicity questionnaire when transitioning from inpatient to outpatient care - Assess patient response to bispecific therapy, with a focus on toxicity management and safely transitioning these patients to outpatient treatment
Methods: Prospective, single-center, descriptive study
Results: Results pending
Conclusion: Results pending
References (must also be included in final poster): 1. Kegyes, D., Constantinescu, C., Vrancken, L. et al. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?. J Hematol Oncol 15, 78 (2022). https://doi.org/10.1186/s13045-022-01296-2
